News GSK takes fight to AZ/Merck & Co with first-line ovarian can... The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class
Events Partner Content PARP & DNA Damage Response Inhibitors Summit 2020 PARP DNA Damage Response Summit DDR Synthetic Lethality
News ESMO 2019 – new data could unlock bigger market for PARP inh... AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l
News FDA finally okays Novavax's COVID-19 jab, with restrictions The FDA has granted full approval to Novavax's COVID-19 vaccine after a delay, but has limited its use.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.